Alaunos Non Current Assets Total vs Cash Analysis

TCRT Stock

USD 2.97 0.12 4.21%

Alaunos Therapeutics financial indicator trend analysis is way more than just evaluating Alaunos Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Alaunos Therapeutics is a good investment. Please check the relationship between Alaunos Therapeutics Non Current Assets Total and its Cash accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Alaunos Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For more information on how to buy Alaunos Stock please use our How to Invest in Alaunos Therapeutics guide.

Non Current Assets Total vs Cash

Non Current Assets Total vs Cash Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Alaunos Therapeutics Non Current Assets Total account and Cash. At this time, the significance of the direction appears to have weak relationship.

The correlation between Alaunos Therapeutics' Non Current Assets Total and Cash is 0.35. Overlapping area represents the amount of variation of Non Current Assets Total that can explain the historical movement of Cash in the same time period over historical financial statements of Alaunos Therapeutics, assuming nothing else is changed. The correlation between historical values of Alaunos Therapeutics' Non Current Assets Total and Cash is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Assets Total of Alaunos Therapeutics are associated (or correlated) with its Cash. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash has no effect on the direction of Non Current Assets Total i.e., Alaunos Therapeutics' Non Current Assets Total and Cash go up and down completely randomly.

Correlation Coefficient

0.35

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Non Current Assets Total

The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.

Cash

Cash refers to the most liquid asset of Alaunos Therapeutics, which is listed under current asset account on Alaunos Therapeutics balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Alaunos Therapeutics customers. The amounts must be unrestricted with restricted cash listed in a different Alaunos Therapeutics account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.

Most indicators from Alaunos Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Alaunos Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Alaunos Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For more information on how to buy Alaunos Stock please use our How to Invest in Alaunos Therapeutics guide.Sales General And Administrative To Revenue is likely to gain to 2,309 in 2025, whereas Selling General Administrative is likely to drop slightly above 4.2 M in 2025.

	2022	2023	2024	2025 (projected)
Cost Of Revenue	2.8M	4.8M	5.5M	5.8M
Reconciled Depreciation	2.8M	2.8M	2K	1.9K

Cost Of Revenue Reconciled Depreciation

Alaunos Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Intangible Assets	Other Current Liab	Total Current Liabilities	Accounts Payable	Common Stock	Property Plant And Equipment Net	Short Term Investments	Current Deferred Revenue	Other Liab
Total Assets		-0.37	0.38	-0.94	0.07	0.97	0.5	0.26	0.46	0.97	0.52	-0.14	0.62	0.45	-0.02	0.5	0.99	-0.43	0.82	0.79	0.4	0.63	0.38	0.53	0.48	0.19
Short Long Term Debt Total	-0.37		-0.04	0.53	-0.71	-0.4	0.22	-0.25	-0.62	-0.4	-0.14	0.75	-0.26	-0.4	0.7	-0.32	-0.42	-0.24	-0.49	-0.13	-0.14	-0.04	0.45	-0.3	-0.37	-0.66
Total Stockholder Equity	0.38	-0.04		-0.39	0.13	0.43	0.15	-0.3	-0.16	0.43	0.63	0.03	-0.3	-0.19	0.07	-0.54	0.38	-0.16	0.4	0.12	-0.22	0.32	0.41	0.19	-0.48	-0.32
Net Debt	-0.94	0.53	-0.39		-0.27	-0.98	-0.22	-0.15	-0.61	-0.98	-0.4	0.3	-0.66	-0.37	0.21	-0.43	-0.97	0.38	-0.81	-0.63	-0.36	-0.38	-0.14	-0.48	-0.53	-0.39
Retained Earnings	0.07	-0.71	0.13	-0.27		0.19	-0.35	-0.05	0.52	0.19	-0.2	-0.97	0.13	-0.09	-0.98	-0.1	0.12	0.52	0.23	-0.06	-0.02	-0.05	-0.37	0.38	0.06	0.77
Cash	0.97	-0.4	0.43	-0.98	0.19		0.35	0.13	0.53	1.0	0.43	-0.23	0.66	0.32	-0.13	0.41	0.98	-0.4	0.81	0.72	0.37	0.5	0.31	0.51	0.48	0.31
Non Current Assets Total	0.5	0.22	0.15	-0.22	-0.35	0.35		0.53	-0.12	0.35	0.49	0.27	0.08	0.18	0.36	0.23	0.4	-0.24	0.4	0.62	0.44	0.75	0.78	0.31	-0.01	-0.34
Non Currrent Assets Other	0.26	-0.25	-0.3	-0.15	-0.05	0.13	0.53		0.35	0.13	0.03	-0.08	0.22	0.44	-0.03	0.45	0.2	-0.14	0.2	0.27	0.65	0.19	-0.11	0.17	0.34	0.09
Other Assets	0.46	-0.62	-0.16	-0.61	0.52	0.53	-0.12	0.35		0.53	-0.31	-0.6	0.65	0.33	-0.56	0.41	0.5	-0.29	0.49	0.39	0.45	-0.05	-0.41	0.37	0.63	0.8
Cash And Short Term Investments	0.97	-0.4	0.43	-0.98	0.19	1.0	0.35	0.13	0.53		0.43	-0.23	0.66	0.32	-0.13	0.41	0.98	-0.4	0.81	0.72	0.37	0.5	0.31	0.51	0.48	0.31
Net Receivables	0.52	-0.14	0.63	-0.4	-0.2	0.43	0.49	0.03	-0.31	0.43		0.23	-0.23	0.27	0.31	0.0	0.48	-0.15	0.52	0.22	-0.11	0.54	0.56	0.2	-0.26	-0.47
Common Stock Shares Outstanding	-0.14	0.75	0.03	0.3	-0.97	-0.23	0.27	-0.08	-0.6	-0.23	0.23		-0.27	-0.06	0.99	-0.12	-0.19	-0.49	-0.25	-0.05	-0.08	-0.04	0.38	-0.49	-0.23	-0.84
Non Current Liabilities Total	0.62	-0.26	-0.3	-0.66	0.13	0.66	0.08	0.22	0.65	0.66	-0.23	-0.27		0.35	-0.21	0.71	0.65	-0.23	0.35	0.53	0.47	0.14	-0.08	0.29	0.9	0.59
Other Current Assets	0.45	-0.4	-0.19	-0.37	-0.09	0.32	0.18	0.44	0.33	0.32	0.27	-0.06	0.35		0.03	0.62	0.46	-0.21	0.33	0.25	-0.03	0.28	-0.14	0.23	0.47	0.04
Other Stockholder Equity	-0.02	0.7	0.07	0.21	-0.98	-0.13	0.36	-0.03	-0.56	-0.13	0.31	0.99	-0.21	0.03		-0.03	-0.07	-0.53	-0.17	0.05	-0.04	0.08	0.43	-0.41	-0.17	-0.84
Total Liab	0.5	-0.32	-0.54	-0.43	-0.1	0.41	0.23	0.45	0.41	0.41	0.0	-0.12	0.71	0.62	-0.03		0.5	-0.22	0.33	0.51	0.5	0.28	-0.08	0.27	0.78	0.36
Total Current Assets	0.99	-0.42	0.38	-0.97	0.12	0.98	0.4	0.2	0.5	0.98	0.48	-0.19	0.65	0.46	-0.07	0.5		-0.42	0.82	0.75	0.37	0.57	0.31	0.52	0.51	0.25
Intangible Assets	-0.43	-0.24	-0.16	0.38	0.52	-0.4	-0.24	-0.14	-0.29	-0.4	-0.15	-0.49	-0.23	-0.21	-0.53	-0.22	-0.42		-0.4	-0.43	-0.31	-0.04	-0.17	-0.04	-0.16	0.23
Other Current Liab	0.82	-0.49	0.4	-0.81	0.23	0.81	0.4	0.2	0.49	0.81	0.52	-0.25	0.35	0.33	-0.17	0.33	0.82	-0.4		0.72	0.35	0.45	0.31	0.5	0.23	0.25
Total Current Liabilities	0.79	-0.13	0.12	-0.63	-0.06	0.72	0.62	0.27	0.39	0.72	0.22	-0.05	0.53	0.25	0.05	0.51	0.75	-0.43	0.72		0.59	0.72	0.52	0.53	0.43	0.18
Accounts Payable	0.4	-0.14	-0.22	-0.36	-0.02	0.37	0.44	0.65	0.45	0.37	-0.11	-0.08	0.47	-0.03	-0.04	0.5	0.37	-0.31	0.35	0.59		0.2	0.04	0.24	0.5	0.32
Common Stock	0.63	-0.04	0.32	-0.38	-0.05	0.5	0.75	0.19	-0.05	0.5	0.54	-0.04	0.14	0.28	0.08	0.28	0.57	-0.04	0.45	0.72	0.2		0.74	0.59	0.07	-0.13
Property Plant And Equipment Net	0.38	0.45	0.41	-0.14	-0.37	0.31	0.78	-0.11	-0.41	0.31	0.56	0.38	-0.08	-0.14	0.43	-0.08	0.31	-0.17	0.31	0.52	0.04	0.74		0.23	-0.28	-0.46
Short Term Investments	0.53	-0.3	0.19	-0.48	0.38	0.51	0.31	0.17	0.37	0.51	0.2	-0.49	0.29	0.23	-0.41	0.27	0.52	-0.04	0.5	0.53	0.24	0.59	0.23		0.21	0.36
Current Deferred Revenue	0.48	-0.37	-0.48	-0.53	0.06	0.48	-0.01	0.34	0.63	0.48	-0.26	-0.23	0.9	0.47	-0.17	0.78	0.51	-0.16	0.23	0.43	0.5	0.07	-0.28	0.21		0.59
Other Liab	0.19	-0.66	-0.32	-0.39	0.77	0.31	-0.34	0.09	0.8	0.31	-0.47	-0.84	0.59	0.04	-0.84	0.36	0.25	0.23	0.25	0.18	0.32	-0.13	-0.46	0.36	0.59

Click cells to compare fundamentals

Alaunos Therapeutics Account Relationship Matchups

Alaunos Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	146.3M	94.9M	64.9M	8.3M	2.8M	2.6M
Total Stockholder Equity	124.0M	58.1M	38.6M	6.3M	2.1M	2.0M
Net Debt	(110.3M)	(46.0M)	(19.0M)	(6.1M)	(1.1M)	(1.1M)
Retained Earnings	(764.1M)	(842.9M)	(880.6M)	(915.8M)	(920.4M)	(874.4M)
Cash	115.1M	76.1M	39.1M	6.1M	1.1M	1.0M
Non Current Assets Total	3.6M	15.8M	16.0M	11.1M	2K	0.0
Non Currrent Assets Other	9.6M	240K	875K	673K	542K	0.0
Other Assets	875K	673K	542K	1.0	0.9	0.86
Cash And Short Term Investments	115.1M	76.1M	39.1M	6.1M	1.1M	1.0M
Net Receivables	4.7M	1.1M	4K	1K	5K	4.8K
Common Stock Shares Outstanding	1.4M	1.4M	1.4M	1.6M	1.6M	1.7M
Liabilities And Stockholders Equity	146.3M	94.9M	64.9M	8.3M	2.8M	2.6M
Non Current Liabilities Total	4K	1.6M	4.0M	20.8M	2.2M	0.0
Other Current Assets	10.9M	1.7M	799K	2.2M	1.7M	1.6M
Other Stockholder Equity	887.9M	900.7M	918.9M	922.1M	922.5M	968.6M
Total Liab	22.4M	36.8M	26.4M	2.0M	692K	657.4K
Total Current Assets	130.6M	78.8M	53.8M	8.3M	2.8M	2.6M
Other Current Liab	16.6M	5.3M	4.9M	1.3M	176K	167.2K
Total Current Liabilities	18.4M	16.0M	24.2M	2.0M	692K	657.4K
Accounts Payable	960K	1.4M	1.4M	616K	516K	490.2K
Common Stock	215K	216K	240K	16K	2K	1.9K
Property Plant And Equipment Net	3.4M	14.9M	15.4M	10.6M	2K	0.0
Net Tangible Assets	95.0M	124.0M	58.1M	38.6M	44.3M	55.8M
Property Plant Equipment	3.4M	14.9M	15.4M	8.5M	9.7M	8.1M
Net Invested Capital	124.0M	82.2M	55.3M	6.3M	2.1M	2.0M
Capital Stock	215K	216K	240K	16K	2K	1.9K
Net Working Capital	112.2M	62.8M	29.6M	6.3M	2.1M	2.0M
Property Plant And Equipment Gross	19.8M	22.8M	8.5M	15K	13.5K	12.8K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Alaunos Stock Analysis

When running Alaunos Therapeutics' price analysis, check to measure Alaunos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alaunos Therapeutics is operating at the current time. Most of Alaunos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Alaunos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alaunos Therapeutics' price. Additionally, you may evaluate how the addition of Alaunos Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC